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Summary 
Centrioles are essential for cilia and centrosome assembly. In centriole-containing 
cells, centrioles always form juxtaposed to pre-existing ones, a century old 
observation that motivates a long-standing debate on spatial control of centriole 
biogenesis. Here, we show that trans-autoactivation of Polo-like kinase 4 (PLK4) is a 
critical early event in centriole biogenesis. A mathematical model suggests this 
process requires PLK4 accumulation above a threshold concentration. We 
demonstrate that centrioles promote PLK4 activation through its recruitment and 
local accumulation. Though centriole removal reduces the proportion of active PLK4, 
this can be rescued by concentrating PLK4 to the peroxisome lumen. Moreover, we 
show that at low levels of overexpression, PLK4 only triggers centriole biogenesis at 
the existing centriole, while higher levels can trigger biogenesis at the centriole as 
well as anywhere in the cytoplasm (de novo). Hence, centrioles promote their 
assembly locally, and disfavour indiscriminate de novo synthesis. Mechanisms 
involving the local concentration of other centriole components are likely to enforce 
the formation of new centrioles always juxtaposed to pre-existing ones under 
physiological conditions. 
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Introduction 
Centrioles are microtubule-based structures essential for cilia and centrosome 
formation (Bettencourt-Dias and Glover, 2007; Nigg and Stearns, 2011). In each cell 
cycle one and only one centriole is formed in a highly controlled fashion close to an 
already existing centriole (canonical biogenesis) (Bettencourt-Dias and Glover, 2007; 
Nigg and Stearns, 2011). Centrioles can also form in the absence of a pre-existing 
centriole (de novo biogenesis). De novo formation is known to occur in insect species 
with parthenogenic development, i.e. development without fertilization, as oocytes 
normally lose their centrioles during oogenesis (Cunha-Ferreira et al., 2009). Human 
cells can also form centrioles de novo upon laser ablation of their centrosome 
(LaTerra et al., 2005). In most circumstances, de novo centriole assembly is slower 
when compared to the canonical pathway, with centrioles forming in highly variable 
numbers and presumably anywhere in the cell (Cunha-Ferreira et al., 2009). 
Intriguingly, the presence of a single centriole is sufficient to prevent de novo 
assembly (LaTerra et al., 2005; Marshall et al., 2001). This preference for canonical 
biogenesis allows the strict control in timing and number, allowing for biogenesis to 
be regulated by the multitude of signalling proteins, such as p53, that localize to the 
centrosome (Bettencourt-Dias and Glover, 2007; Nigg and Stearns, 2011). So how 
do existing centrioles control where new centrioles form? One possibility is that 
centrioles release an ‘inhibitor of centriole biogenesis’ (Marshall et al., 2001). 
Alternatively, pre-existing centrioles might catalyze centriole assembly, perhaps by 
preferentially recruiting centriole precursors or by locally activating them (Marshall et 
al., 2001; Rodrigues-Martins et al., 2007). What could be the nature of such 
inhibitors/catalyzers of new centriole formation? Regulation of Polo Like Kinase 4 
(PLK4), a major player in centriole biogenesis, might play a very important role in the 
spatial regulation of centriole biogenesis. In the absence of PLK4 no centrioles are 
formed (Bettencourt-Dias et al., 2005; Habedanck et al., 2005). PLK4 in excess 
triggers multiple centriole formation at the centrosome in cycling cells (canonical 
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amplification) (Habedanck et al., 2005; Kleylein-Sohn et al., 2007; Rodrigues-Martins 
et al., 2007) and de novo assembly in acentriolar systems, such as Drosophila 
unfertilized eggs (Peel et al., 2007; Rodrigues-Martins et al., 2007). However, de 
novo biogenesis is slower when compared to the canonical centriole biogenesis 
observed in fertilized Drosophila eggs expressing the same levels of PLK4 
(Rodrigues-Martins et al., 2007). This supports a model where centrioles catalyze 
their own assembly and where PLK4 levels, and consequently its activity, are a 
limiting factor in both canonical and de novo centriole formation. As other protein 
kinases, PLK4 function is likely to be strongly determined by protein concentration 
and regulation of its kinase activity (Zitouni et al., 2014). It is known that PLK4 levels 
are controlled by a negative feedback loop mediated by PLK4 trans-
autophosphorylation on a specific degron sequence downstream of its catalytic 
domain that is recognized by the SCF-Slimb/βTrCP ubiquitin ligase complex (Cunha-
Ferreira et al., 2013; Holland et al., 2010; Klebba et al., 2013). However, little is 
known about the regulation of its kinase activity. Here, we set out to investigate how 
PLK4 activity is regulated and whether centrioles might catalyze this process. 
 
Results 
Phosphorylation of Drosophila PLK4 Thr172 is required for its catalytic activity 
Activation of PLK1, the founding member of the Polo family, involves phosphorylation 
of one critical residue within its T-Loop in the catalytic domain (Archambault and 
Carmena, 2012; Zitouni et al., 2014), which is highly conserved in PLK4 (Fig. 1A). 
While different mechanisms may be involved in PLK4 activation, we first asked if this 
residue in PLK4 had a role in its activation. We observed phosphorylation of the 
equivalent residue in PLK4 (Threonine 172) using mass spectrometry (not shown). 
To confirm the role of Thr172 phosphorylation for PLK4 activity, we used two 
readouts: the ability of PLK4 to trans-autophosphorylate in another residue, which is 
located in its degron (Ser293 (Cunha-Ferreira et al., 2013), Figures 1B), and its 
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ability to phosphorylate an exogenous substrate (Myelin Basic Protein – MBP,  
Figure S1A). The catalytic activity of PLK4(T172A), a mutant where Thr172 was 
mutated to alanine to mimic its non-phosphorylated state, was significantly reduced 
as compared to PLK4 wild type (WT; Figures 1B and S1A). Kinase dead PLK4 (KD; 
bears three mutations in the kinase catalytic site: K43M, K22M and D156A 
(Rodrigues-Martins et al., 2008)) showed no activity as expected. It is important to 
note that the T172A mutation preventing activation of PLK4 also affected its steady-
state stability, as the mutant is much more stable, similarly to a kinase dead PLK4 
(Figure S1B). This is consistent with previous studies demonstrating that a 
catalytically inactive PLK4 is more stable as it cannot autophosphorylate in a degron 
that targets itself for degradation (Cunha-Ferreira et al., 2013; Holland et al., 2010; 
Klebba et al., 2013). Moreover, impairment of PLK4´s ability to be phosphorylated at 
residue Thr172, from hereinafter called ‘PLK4 activation’, also had strong 
consequences in its centriole biogenesis function (Figures 1C-D). Similar to the 
kinase dead, expression of PLK4(T172A) could not rescue the accumulation of cells 
with an abnormally low number of centrioles (less than 2) that arose from depletion of 
endogenous PLK4 (Figures 1C-D; category ‘0-1’). Together, these data suggest that 
though Thr172 non-phosphorylated PLK4 has residual catalytic activity (Figure 1B), 
this is not sufficient to drive centriole biogenesis (Figure 1C-D).  
 
PLK4 regulates its own kinase activity by autophosphorylating Thr172 
The identity of the kinase that activates PLK4 in an unperturbed cell is hitherto 
unknown. The activating phosphorylation of the T-loop of a kinase can either be 
mediated by another kinase (e.g. PLK1 (Zitouni et al., 2014)) or it can be 
autocatalytic (e.g. Aurora A (Adams, 2003)). Stress-activated protein kinases 
(SAPKKK (Nakamura et al., 2013)) can phosphorylate human PLK4 Thr170, the 
equivalent residue to Drosophila Thr172 (Figure 1A), upon cellular stress. However, 
multiple RNAi screens in unperturbed cells failed to identify a kinase whose activity is 
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required for PLK4´s function (Balestra et al., 2013; Bettencourt-Dias et al., 2005; 
Brownlee et al., 2011; Dobbelaere et al., 2008; Goshima et al., 2007). Since PLK4 
kinase domain can autophosphorylate in vitro (Dodson et al., 2013), we therefore 
proceeded to test whether PLK4 autoactivates in a normal cell cycle.  
 We generated and tested a phospho-specific antibody (p-PLK4 Thr172) in 
vitro and cycling cell extracts (see loss of signal upon phosphatase treatment and 
T172A mutation in Figures 2A-B, and S2A). Full length bacterially expressed GST-
PLK4(WT) showed Thr172 phosphorylation and reduced gel mobility, suggestive of 
autophosphorylation, which was not observed upon phosphatase co-expression (λ-
ppase) (Shrestha et al., 2012) or expression of kinase dead PLK4 (KD; Figure 2A). 
These results show that PLK4 kinase catalytic activity is required and sufficient for its 
autophosphorylation at Thr172 in vitro. We observed the same result by adding ATP 
to dephosphorylated His-MBP-PLK4(WT) (Fig. S2B). Autophosphorylation of Thr172 
was observed very early upon ATP addition and increased with time (Fig. S2B), 
showing that Thr172 dephosphorylated PLK4 has ‘residual catalytic activity’ thus 
being able to autophosphorylate. To test whether PLK4 Thr172 autophosphorylation 
activates PLK4, we compared the catalytic activity of PLK4 species with different 
levels of phosphorylation in this residue (Figure S2C). Our results show that PLK4 
with higher levels of phosphorylation in Thr172 was more efficient in substrate 
phosphorylation (Figure S2C), suggesting that Thr172 phosphorylation correlates 
with activity. Although our data does not exclude that full PLK4 activation may be 
more complex, with other autophosphorylated residues (Klebba et al., 2015a) 
potentially also playing a role in PLK4 autoactivation, it strongly suggests that Thr172 
is an important residue in this function. 
 Finally, we asked whether PLK4 also autoactivated in cells in an unperturbed 
cell cycle. We found that Thr172 was not phosphorylated when only the kinase dead 
(KD) mutant was expressed in the absence of endogenous PLK4 (Figure 2B). 
Furthermore, we observed the same results even upon expression of very high levels 
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of PLK4 (PLK4 non-degradable, i.e. that cannot be targeted for degradation, ND, and 
PLK4 non-degradable kinase dead, KDND (Cunha-Ferreira et al., 2009); Figure 2B). 
These results show that PLK4 can autoactivate in cells in an unperturbed cell cycle.  
 Autophosphorylation is common to many kinases, but it can be achieved 
through multiple molecular mechanisms, which result in different kinetic properties. 
Mps1, a kinase involved in mitotic checkpoint signalling, autophosphorylates and 
activates in trans (Jelluma et al., 2008; Kang et al., 2007; Mattison et al., 2007). 
Other kinases, such as p38, autophosphorylate in cis (DeNicola et al., 2013). To 
further understand the kinetics of PLK4 autophosphorylation (cis vs. trans), we 
investigated the level of phosphorylation at Thr172 by adding ATP to different 
concentrations of dephosphorylated His-MBP-PLK4(WT) (Figure 2C). 
Autophosphorylation of Thr172 increased nonlinearly with increase in PLK4 
concentration (Figure 2C) showing that Thr172-dephosphorylated PLK4 is able to 
autoactivate in trans. To confirm whether PLK4 can autophosphorylate in trans in 
cells at the Thr172 residue we simultaneously expressed GFP-PLK4(WT) and Myc-
PLK4(KD) in the absence of endogenous PLK4 (Figures 2D-E). While individually 
expressed PLK4(WT) is found autophosphorylated at Thr172 (left lane), PLK4(KD) is 
not (middle lane). However, co-expression of both the active (WT) and inactive 
kinases (KD) led to phosphorylation of PLK4(KD) at the Thr172 residue (right lane) 
by the co-expressed active PLK4(WT), demonstrating autophosphorylation in trans 
(Figures 2D-E). 
 
PLK4 activation is dependent on its localized accumulation  
To investigate the implications of a PLK4 trans-autoactivation mechanism in the 
spatial regulation of centriole biogenesis, we generated a simple mathematical model 
of PLK4 activity. This model takes into account the synthesis of a ‘basal form’ of 
PLK4 (non-Thr172 phosphorylated PLK4 with residual catalytic activity), which is 
activated through phosphorylation of Thr172 in the T-loop, and subsequently 
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targeted for degradation by autophosphorylation in the degron (B, A* and A**, 
respectively, in Figure 3A).  We posit two alternative scenarios for PLK4 activation by 
cis- or trans-autophosphorylation (Figure 3A-B). In contrast to a scenario in which 
PLK4 autophosphorylates in cis (or is phosphorylated by other unknown kinase), the 
positive feedback resulting from PLK4 trans-autophosphorylation gives rise to a 
threshold of total PLK4 concentration (Figure 3B) below which there is little PLK4 
activation, reflecting the unlikely encounters between two PLK4 molecules. 
 An important output of incorporating PLK4 trans-autoactivation in our model is 
that PLK4 is only activated when sufficiently concentrated (Figure 2C). Since PLK4 
localizes to the centrosome it is possible that the organelle acts as a ‘PLK4 
concentrator’, accumulating the kinase until it reaches supra-threshold 
concentrations. To assess this possibility, we elaborated a two-compartment model 
that features an exchange of all PLK4 forms between the cytoplasm and the 
centrosome (Figure 3C). The model assumes that the volume ratio of the two 
compartments is 2000 (Decker et al., 2011), the exchange of PLK4 is biased towards 
the centrosome, and PLK4 basal catalytic activity is twenty times lower than that of 
the activated PLK4 (phosphorylated at Thr172, Figure 1B). Under these 
assumptions, the model indicates that normal PLK4 production can be tuned so that 
it elicits robust PLK4 accumulation and activation at the centrosome while being 
insufficient to trigger PLK4 activation in the cytoplasm (Figure 3D), thus offering a 
mechanism to prevent centriole formation in the cytoplasm. If this holds true, the 
model suggests several outcomes (Figure 3D): i) the absence of PLK4 recruitment to 
the centrosome should lead to little PLK4 trans-autoactivation (Figure 3D, no 
centrosome and no PLK4 overexpression); ii) concentrating PLK4 elsewhere in the 
cell should be sufficient to activate it; iii) PLK4 overexpression at low levels should 
lead to a higher proportion of activated PLK4 at the centrosome and thus canonical 
amplification, or to de novo centriole biogenesis in the absence of the centrosome, 
as reported before (Rodrigues-Martins et al., 2007) as PLK4 is no longer 
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sequestered by this organelle (Figure 3D, PLK4 overexpression +); iv) PLK4 
overexpression at high levels should produce a higher proportion of active PLK4 
forms anywhere in the cytoplasm, therefore eliciting de novo biogenesis even in the 
presence of a pre-existing centrosome, thus overriding the principle of de novo 
biogenesis inhibition by the centrosome (Marshall et al., 2001; Rodrigues-Martins et 
al., 2007) (Figure 3D, PLK4 overexpression ++). We decided to test all predictions, 
particularly the ones that had not been tested in the literature, i.e. i), ii) and iv).  
 
The centrosome is the physiological ‘PLK4 concentrator’ 
We experimentally tested whether PLK4 trans-activation in Thr172 is dependent on 
local concentration of PLK4 at the centrosome (prediction i). We first analyzed 
whether non-phosphorylatable PLK4(T172A) can localize to the centrosome. Indeed, 
similar to PLK4(WT), PLK4(T172A) localized to the centrosome (Figure 4A). We then 
tested if abrogation of PLK4 recruitment to the centrosome would prevent its trans-
activation, by depleting Asterless (Asl, CEP152 in vertebrates), a molecule that is 
needed for PLK4 recruitment to the centrosome (Cunha-Ferreira et al., 2013; 
Dzhindzhev et al., 2010), while expressing PLK4(WT) (Figures 4B-E). Interestingly, 
we have shown in the past that PLK4(KD), which is not phosphorylated in Thr172 
(Figure 2), can still interact with Asl (Cunha-Ferreira et al., 2013). Indeed, depletion 
of Asl led to impaired recruitment of PLK4(WT) to the centrosomes (Figures 4B-C) 
and to the reduction in the number of centrosomes (Figure 4D), as reported before 
(Dzhindzhev et al., 2010). Concomitantly, we saw a reduction in the ratio of PLK4 
phosphorylated in Thr172 (Figure 4E). In agreement with our hypothesis, these 
results strongly suggest that localization of PLK4 at the centrosome is normally 
required for its activation. Finally, to further test whether centrosomes are required 
for PLK4 activation in a more definitive manner, we investigated the ratio of activated 
PLK4(WT) in normal cells vs. acentrosomal cells. In Drosophila tissue culture cells 
we can generate acentrosomal cells by depleting an essential component of the 
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centriole, SAS-6 (Peel et al., 2007; Rodrigues-Martins et al., 2007) for several rounds 
of cell division (more than 8 rounds). As cells divide normally without being able to 
duplicate their centrioles, the population of cells with abnormally low number of 
centrioles (0-1) increases to almost 100% (Rodrigues-Martins et al., 2007) (SAS-6 
RNAi; Figure 5C). We compared the ratio of activated PLK4 (p-PLK4 Thr172) in 
GFP-PLK4(WT)-expressing cells with and without centrioles (mCherry or SAS-6 
RNAi, respectively; Figure 5D, left panel). Whereas we could detect p-PLK4 Thr172 
in cells with centrioles (mCherry RNAi), we were unable to detect this activated PLK4 
form in acentriolar cells (SAS-6 RNAi). As PLK4 becomes more active at the 
centrosome, it is possible that it also autophosphorylates more in its degron, 
targeting itself for degradation (Cunha-Ferreira et al., 2013; Klebba et al., 2013). In 
agreement with this, we observed that PLK4 was more stable in acentriolar cells 
(SAS-6 RNAi; Figure S3A). 
 Together, these results strongly support “prediction i” that PLK4 trans-
activation is normally dependent on its recruitment and concentration at the 
centrosome, suggesting that the centrosome concentrates PLK4. However, our 
experiments do not formally exclude the possibility that perhaps a molecular 
component at the centrosome is catalyzing PLK4 trans-autophosphorylation. We 
therefore tested “prediction ii”, i.e. whether concentration of overexpressed PLK4 
alone outside of the centrosome is sufficient to promote PLK4 trans-
autophosphorylation in cells by accumulating it on the peroxisome lumen or artificially 
on beads.  
 We targeted PLK4 to the peroxisome lumen using the SKL tag, a C-terminal 
peroxisome-targeting sequence responsible for the import of the majority of 
peroxisomal proteins into that organelle (Gould et al., 1989) (Figure 5A). Whereas 
GFP-PLK4(WT) always localized to the centrosomes, GFP-PLK4(SKL) was 
scattered in foci throughout the cytoplasm. In 58% of cells GFP-PLK4(SKL) co-
localized only with the peroxisomal marker mCherry-SKL, while 39% of the cells 
 11 
showed co-localization with both the peroxisome and the centrosome (Figure 5B). 
We then removed the centrosomes from cells as discussed previously, with 
prolonged SAS-6 RNAi, so that GFP-PLK4(SKL) could no longer localize to 
centrosomes but only to peroxisomes, hence focusing on the consequences of 
localizing PLK4 on a different structure than the centrosome (Figure 5C). 
Remarkably, we observed a very strong signal for p-PLK4 Thr172 (Figure 5D, middle 
panel, SAS-6 RNAi), showing that enforced PLK4 concentration is sufficient to lead 
to its activation in cells. We also detected an increase in reduced gel mobility forms 
of total PLK4 when at the peroxisome (GFP-PLK4(SKL); Figure 5D, left and middle 
panels) suggesting that PLK4 might be shielded from phosphatases and/or the SCF-
mediated degradation machinery when concentrated inside that organelle, as 
opposed to the cytoplasm (GFP-PLK4(WT), SAS-6 RNAi) and the centrosome (GFP-
PLK4(WT), mCherry RNAi) ((Brownlee et al., 2011); note that the antibody against 
total PLK4 does not recognize a fraction of hyper-phosphorylated PLK4 that migrates 
slowly and is recognized by the p-PLK4-Thr172 antibody). Furthermore, the ratio of 
Thr172 phosphorylated PLK4 to total PLK4 at the centrosome (PLK4(WT)) and at the 
peroxisome (PLK4(SKL)) was dependent on PLK4 concentration, as expected 
(Figure 5E). Though PLK4 was highly active at the peroxisome lumen, we did not 
observe centriole formation there, likely due to the lack of substrates required for 
centriole biogenesis within that organelle. In fact, Ana2/STIL, a substrate, and 
recently shown activator of PLK4 (Moyer et al., 2015), was not observed at the 
peroxisome (Figure S3B). 
 Finally, we corroborated these findings by artificially concentrating GFP-
PLK4(WT) in beads that bind to more than one GFP molecule. After GFP-PLK4(WT) 
immunoprecipitation from cellular extracts, with consequent concentration on the 
beads, we observed an increase in reduced gel mobility forms and Thr172 
phosphorylation independently of the presence of centrosomes (Figure 5D, right 
panel, mCherry (with centrosomes) or SAS-6 (no centrosomes)). We conclude that, 
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similar to the peroxisome targeting in cells, PLK4-enforced immobilization on beads 
during immunoprecipitation enables trans-autoactivation of PLK4. Together, the 
experiments above described show that the centrosome is a potent promoter of 
PLK4 activation and that this likely works in part through recruitment and 
concentration of PLK4, as replacing the centrosome by the peroxisome or beads 
rescues PLK4´s trans-autoactivation in Thr172.  
 
High levels of PLK4 can overcome the ‘de novo biogenesis inhibition’ 
Finally, we tested “predictions iii and iv”, i.e. that in the presence of centrioles, low 
levels of PLK4 should promote only canonical amplification, while high levels of PLK4 
should overcome the ‘de novo biogenesis inhibition’, leading to the very unusual co-
occurrence of both canonical and de novo amplification. In this case, PLK4 levels 
would be sufficient to lead to its activation, and consequent centriole biogenesis, 
anywhere in the cytoplasm.  
 We chose Drosophila spermatogenesis as an experimental system to test our 
predictions as it provides several advantages (Figure 6A): i) cells within 16-cell cysts 
are in G2 and have two centrosomes, each with two very long (1.25 m) easily 
detectable centrioles (in inset in Figure 6A) and ii) using Bam promoter (BamGal4) 
(Chen and McKearin, 2003) we can ectopically overexpress GFP-PLK4 at different 
levels by simply growing the same flies at different temperatures (from 16ºC to 25ºC) 
as Gal4 expression is very sensitive to temperature. Indeed, we found that the flies 
grown at 16⁰C and 25⁰C overexpress very low and high amounts of PLK4, 
respectively (Figure 6B). While control flies (with no PLK4 overexpression) 
consistently showed two wild-type (WT) centrosomes, each with two centrioles, at all 
temperatures (Type I, shown only for 25ºC in Figure 6C-F), we observed centriole 
amplification, starting in the 16-cell cyst, in PLK4 overexpressing-flies grown at all 
temperatures (Figures 6C-D). The number of centrioles increased with PLK4 
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overexpression levels (Figures 6C-D) with some cells harbouring as many as 25 
centrioles (Figure 6D). 
 At low levels of PLK4 overexpression (16ºC) we found that 25% of the cells 
had only two centrosomes, each with several centrioles forming a rosette (Type III, 
Figures 6C,E). Thus, low PLK4 overexpression promotes canonical amplification in 
spermatocytes, as previously described in many cell types (Cunha-Ferreira et al., 
2009; Kleylein-Sohn et al., 2007). Strikingly, in the remaining 75% of the 
spermatocytes, we detected two rosettes and additional supernumerary clusters of 
centrioles, each containing one or more centrioles (we called them centrosomes for 
simplicity, Type IV, Figures 6C,E-F), suggesting the co-occurrence of canonical and 
de novo amplification in the same cell. In agreement with our model, we observed 
that the number of de novo formed centrosomes increased with PLK4 levels (Figures 
6E-F), showing that high levels of PLK4 in the cytoplasm lead to formation of de novo 
centrosomes even in the presence of pre-existing centrioles.   
 Importantly, we never detected de novo formed centrioles in the presence of 
WT centrosomes (with 2 centrioles) (Type II, Figure 6E) at any of the different levels 
of PLK4 overexpression, suggesting that canonical biogenesis is favoured to de novo 
assembly. This result strongly supports our model in which the centrosome is a 
natural ‘concentrator’ of PLK4, thus promoting its activation. 
 
Discussion  
Why centrioles normally form close to existing centrioles is an intriguing question that 
has fuelled debates about the origin of centrioles as self-replicating entities. Here, we 
asked how control of the activity and local concentration of a major regulator of 
centriole biogenesis, PLK4, contributes to the spatial control of centriole formation. 
We show that phosphorylation of the conserved Thr172 T-loop residue is essential 
for PLK4 kinase activity and function in centriole biogenesis (Figure 1). Furthermore, 
PLK4 trans-autophosphorylates Thr172, hence autoactivates (Figure 2); and as a 
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consequence PLK4´s activation critically depends on its concentration (Figures 3 and 
5). We also demonstrate that the centrosome acts as a natural PLK4 concentrator 
(Figures 4 and 5), as this role can be substituted by concentrating overexpressed 
PLK4 on peroxisomes or beads (Figure 5). Our data shows that in a centrosome-
containing cell, given the naturally low expression of PLK4, its full activation can only 
be attained upon concentration at the centrosome, thus explaining why daughter 
centrioles are formed close to their mothers, thus resembling a self-replicating 
process (Figure 6 and summarised in the model in Figure 7). We also show that at 
sufficiently high levels of PLK4 expression, centrosomes no longer inhibit de novo 
formation (Figures 6 and 7). 
 Our data also explains other conundrums. It suggests that in the absence of 
the centrosome PLK4 remains in the cytoplasm where it is more stable, thus leading 
to a higher cytoplasmic concentration than it normally exists in centrosome-
containing cells. This setting increases the likelihood of stochastic encounters 
between trans-autoactivating PLK4 molecules in the cytoplasm and consequently 
favours the de novo centriole formation (LaTerra et al., 2005) (Figures 3 and S3). In 
centrosome-containing cells, however, recruitment of PLK4 to the centrosome 
disfavours its accumulation and autoactivation in the cytoplasm (Figures 3, 6 and 7), 
hence preventing the de novo synthesis of centrioles. This provides an explanation 
for why centrosomes do not normally form de novo in centrosome-containing cells a 
phenomenon that was not explained previously (LaTerra et al., 2005; Uetake et al., 
2007). In agreement with this, accumulation of active PLK4 by any other means, 
such as preventing its degradation, should also lead to the observation of de novo 
formed centrioles (Wang et al., 2011). The regulation of centriole biogenesis by PLK4 
autophosphorylation is similar to better studied processes of polarity establishment, 
such as the selection of bud site in budding yeast (Li and Bowerman, 2010). In this 
system, in the absence of spatial cues, intrinsic mechanisms, including positive 
feedback loops, amplify small and stochastic asymmetries thus breaking symmetry to 
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establish polarity and to form a bud. If spatial cues such as bud scars are present, 
they orient polarity by biasing the site of amplification of asymmetry. Here, the 
centriole is the entity that biases the site of amplification. Similar local positive 
feedback circuits may operate in the spatial inheritance of other cellular structures. 
 We had previously described a negative feedback loop involving PLK4 trans-
autophosphorylation in a degron that targets PLK4 for degradation through an 
ubiquitin ligase complex Slimb/-TRCP (Cunha-Ferreira et al., 2009, 2013). Here, we 
describe a positive feedback loop where PLK4 activation is positively regulated by its 
own concentration. Our and others work suggest that PLK4 is translated and 
recruited to the centrosome where it accumulates (Cizmecioglu et al., 2010; 
Dzhindzhev et al., 2010; Fode et al., 1996; Hatch et al., 2010; Sillibourne et al., 2010; 
Sonnen et al., 2012) until it reaches a threshold that quickly leads to full activation of 
the kinase, which is essential to trigger centriole biogenesis. The active PLK4 will 
then target itself for degradation (Cunha-Ferreira et al., 2013; Holland et al., 2010; 
Klebba et al., 2013). It is likely that both activation and degradation of PLK4 at the 
centrosome and in the cytoplasm might be further regulated by many variables such 
as: i) phosphorylation of other residues in PLK4 (Klebba et al., 2015a); ii) state of 
oligomerization of PLK4 (Klebba et al., 2015a, 2015b), iii) interactions with scaffold 
proteins such as Asl/CEP152 (Klebba et al., 2015b), iv) interactions with its 
substrates and recently shown activators, such as Ana2/STIL (Moyer et al., 2015; 
Ohta et al., 2014), with phosphatases (Brownlee et al., 2011), and other proteins (Xu 
et al., 2014). In the future, it will be critical to study the regulation of the “activating” 
and degron-phosphorylation events in PLK4, and how they generate a lag time 
during which PLK4 can be active to phosphorylate its substrates in the right place 
and at the right time. In addition, it will be important to understand when during the 
cell cycle PLK4 reaches its critical threshold concentration to trigger centriole 
assembly and how this is regulated.  
 Catalysis of centriole biogenesis at existing centrioles may present 
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advantages to the eukaryotic cell, namely the control of centriole number and 
localization. In fact, de novo centrioles, form in random numbers and locations in 
cells without pre-existing centrioles (Bettencourt-Dias and Glover, 2007; LaTerra et 
al., 2005; Rodrigues-Martins et al., 2007; Shang et al., 2002). To our knowledge, 
centrioles are formed close to existing centrioles in all known species that have 
centrioles. This is true for species that have centrioles within the context of 
centrosomes, such as most animals, and also in species that have many centrioles 
forming cilia (called basal bodies) at the cortex, such as ciliates (Carvalho-Santos et 
al., 2011). Daughter centrioles form and remain very close to their mothers until 
mitotic exit, when they come apart and become competent to nucleate daughters. 
This mechanism ensures centriole duplication only occurs once per cell cycle (Nigg 
and Stearns, 2011). Therefore, spatial regulation of biogenesis enforces control of 
centriole number. Spatial control is also important for geometrical organization of the 
cell and movement, as it defines the localization of microtubule organizing centres, 
such as the centrosome and cilia/flagella. For example, in the multiciliate 
Tetrahymena, new basal bodies are formed close to their mothers, so that new cilia 
form within cortical rows with the right orientation in the right place. When centrioles 
form de novo in ciliates, they are not equally distributed across the cortex and the 
organism can show transient defective motility (Shang et al., 2002). 
 Is PLK4 the only centriole component whose biochemical properties provide 
spatial constraints to centriole biogenesis? While the last common ancestor of 
eukaryotes was likely to have centrioles/basal bodies and molecules that are 
necessary for its biogenesis, such as SAS-6, PLK4 only exists in Opistokhonts 
(animals and fungi) (Carvalho-Santos et al., 2010, 2011). It is possible that other 
kinases, such as the ancestral member of the Polo kinase family, played the same 
role and was regulated in a similar concentration-dependent manner. However, it is 
also possible that other components of the centrosome are regulated in a similar 
fashion; indeed, it was recently shown that human SAS-6 is present in the cytoplasm 
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primarily as a homodimer and that its oligomerization into a centriole precursor 
structure occurs at centrioles, where SAS-6 is known to concentrate (Keller et al., 
2014). So the local regulation of several centriole components may contribute to the 
spatial accuracy of centriole biogenesis.  
 PLK4 is upregulated and associated with bad prognosis in breast cancer and 
its deregulation causes microcephaly and cancer (Marthiens et al., 2013; Mason et 
al., 2014). Significantly, inhibitors of this kinase have been recently reported and are 
now in clinical trials for breast cancer treatment (Mason et al., 2014; Wong et al., 
2015). Understanding how PLK4 activity is regulated is thus critical to understand the 
effects of drugs that target this enzyme, the potential mechanisms of resistance to be 
counteracted and to rationally define which tumours are drug-sensitive. Markers of 
PLK4 activity, such as phosphorylation of the activation T-loop residue described in 
this work, might also be used to aid in patients’ stratification for clinical decisions, 
including whether to enrol in surveillance programs and choice of therapy. 
 
Experimental Procedures 
Plasmid constructs  
All the vectors used in this study were constructed using the Gateway system 
(Invitrogen, USA) according to the manufacturer instructions. The pAWM destination 
vector (with Myc tag and Actin 5C promoter) was acquired at DRGC (Indiana, USA). 
The pACYC-RIL-λppase for expression in E. coli was a kind gift from Dr. Jonathan M. 
Elkins (Oxford University, UK) (Shrestha et al., 2012). The GFP N-terminal plasmid 
was a kind gift of João Rocha (University of Cambridge, UK). The PLK4 entry vector 
has been described elsewhere (Bettencourt-Dias et al., 2005). The GFP C-terminal 
PLK4(WT) plasmid was a gift from Dr. Gregory C. Rogers (University of Arizona, 
USA). The mCherry-SKL vector (with Actin 5C promoter) was kindly provided by 
Vladimir Gelfand (Northwestern University School of Medicine, USA). His-MBP 
(PET41A) derived from PET22b(+) was a kind gift from Arie Geerlof (EMBL, 
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Germany). The dicistronic vector pGEX-2RBS (created by Anna De Antoni) was a 
kind gift from Andrea Musacchio (Milan, Italy) (Ciferri et al., 2005). The pGEX-2RBS-
GST-PLK4(WT) and PLK4(KD) have been described elsewhere (Cunha-Ferreira et 
al., 2013). The PLK4 Kinase Dead (KD) mutant includes three mutations in the PLK4 
catalytic domain of PLK4: K43M in the nucleotide binding motif, K22M in the 
phosphate anchor, and D156A in the activation loop. This mutant has been 
described elsewhere (Rodrigues-Martins et al., 2008). Non-degradable PLK4(ND) 
mutant includes two mutations within the DSGIIT degron, S293A and T297A. This 
mutant has been described in (Cunha-Ferreira et al., 2009). The PLK4(KDND) 
mutant includes three mutations within the activation segment: K43M, K22M, D156A 
and two additional mutations within the DSGIIT degron: S293A and T297A. This 
mutant has been has been described elsewhere (Cunha-Ferreira et al., 2013). To 
create the PLK4(T172A) and PLK4(SKL) mutants we used the Quick Change XL 
Site-Directed mutagenesis kit (Stratagene, Santa Clara, USA), according to the 
manual instructions. The PLK4 entry vector was used to mutate Thr172 to alanine. 
PLK4(SKL) was constructed by performing site-directed mutagenesis on the PLK4 
entry vector to add the tripeptide sequence S (Serine) – K (Lysine) – L (Leucine) at 
the C-terminus region of PLK4, as previously described (Gould et al., 1989). The 
primers used for site-directed mutagenesis are listed below. All the constructs were 
sequenced and confirmed prior to recombination into destination vectors.  
 
List of primers used for PLK4 site-directed mutagenesis 
Name Forward (5’-3’) Reverse (5’-3’) 
PLK4(T172A) 
CCTGATGAGCGCCATATGGCCATG
TGTGGAACTCCGAAC 
GTTCGGAGTTCCACACATGGCCATATG
GCGCTCATCAGG 
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PLK4(SKL) 
AATCGCATGCTTCTTAGCAAGCTGT
AAGACCCAGCTTTCTTGTAC 
GTACAAGAAAGCTGGGTCTTACAGCTT
GCTAAGAAGCATGCGATT 
 
 
Protein depletion and transient plasmid transfection  
Drosophila cells (DMEL) were cultured in Express5 SFM (Gibco,USA) supplemented 
with 1x L-Glutamine-Penicilin-Streptomycin according to standard tissue culture 
techniques. dsRNA synthesis against mCherry, ePLK4, SAS-6 and Asl was 
performed as previously described (Bettencourt-Dias et al., 2004). dsRNA for 
endogenous PLK4 (ePLK4) was synthesized from genomic DNA with an adjustment 
of the PCR annealing temperature to 45ºC. For transient transfection of dsRNA, we 
used 2 million cells and 40 μg of dsRNA. In the case of ePLK4, we used a 
combination of 30 μg of ePLK4 3’ dsRNA, with 30 μg of ePLK4 5’ dsRNA. For the 
respective control experiments, we used 60 μg of mCherry dsRNA. Transient 
transfection with SAS-6 dsRNA was performed every 4 days during a total period of 
12 days. The same protocol was adopted for the corresponding mCherry dsRNA 
control experiments. In Asl depletion, two rounds of transient transfection with 30 µg 
of Asl dsRNA every 4 days were performed. mCherry dsRNA was used as a control. 
The primers used for the production of dsRNA are listed below. Transient plasmid 
transfections were performed with Effectene reagent (Qiagen, USA) according to the 
manual recommendations. Briefly, 3 million DMEL cells were plated per well (6-well 
plate) in 1 ml antibiotic-free medium; 400 ng of plasmid DNA were mixed with 3,5 μl 
Enhancer reagent and incubated for 5 min at RT; 10 μl Effectene transfection 
reagent were added to the previous solution, mixed and incubated at RT for 10 min; 
2 ml antibiotic-free medium were added to the final mix and the solution was added 
to the cells in a drop wise manner. Transfections proceeded for 4 days at 25ºC. In 
experiments where the cells had previously been treated with dsRNA, plasmid 
 20 
transfection was performed on the second day of the depletion. In transient 
transfections with pMT-derived constructs, induction with CuSO4 was initiated 15 
hours before harvesting. 
 
List of primers used for dsRNA synthesis 
Name 
CG 
number 
Forward (5’-3’) Reverse (5’-3’) 
mCherry - 
TAATACGACTCACTATAGGGATG
GTGAGCAAGGG 
TAATACGACTCACTATAGGGGTT
GACGTTGTAGG 
Sas-6 15524 
TAATACGACTCACTATAGGGAGA
TGTAGTGCGCATGCTGAAGGAC 
TAATACGACTCACTATAGGGAGA
GCTGCGCTGCTCGTTTATTTTG 
ePLK4 5’ 7186 
TAATACGACTCACTATAGGGAGA
ATTAATCCCAGGGCTGCATTA 
TAATACGACTCACTATAGGGAGA
AGCTAGCCTTTTTTCTGTAGAC 
ePLK4 3’ 7186 
TAATACGACTCACTATAGGGAGA
TAATTGAATCAAAACTTAATTC 
TAATACGACTCACTATAGGGAGA
AACCTCACACTTATACAAAAAG 
Asl 2919 
TAATACGACTCACTATAGGGAGA
TTATGGTGAATGCCTTCGAC 
TAATACGACTCACTATAGGGAGA
CTAGCTCAGCCTGCATGATG 
 
Preparation of whole cell protein extracts  
Whole cell lysates were prepared by resupending cell pellets in lysis buffer 
containing 75 mM HEPES pH 6.8, 150 mM NaCl, 2mM MgCl2, 0.1% NP-40, 5 mM 
DTT, 5% glycerol, 2 mM EGTA and supplemented with phosphatase inhibitors (200 
mM NaF, 150 mM β-glycerophosphate, 1 mM Na3VO4) (all chemicals from Sigma, 
USA) and 1x EDTA-free protease inhibitors (Roche). Laemmli buffer was added to 
the samples to 1x and then boiled at 99ºC for 5 minutes (min) and centrifuged at 
14,000 rpm for 1 min before being analyzed on polyacrylamide gels. The lysate 
soluble and insoluble fractions were separated by centrifugation at 14,000 rpm for 10 
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min. The pellet was resuspended in 0.8 M urea and 1x Laemmli buffer. The extract 
was then boiled at 99ºC for 5 min and centrifuged at 14,000 rpm for 1 min before 
being analyzed on polyacrylamide gels.  
 
Phosphatase treatments 
Whole cell lysates were treated for 30 min at 30ºC with 400 U of lambda 
phosphatase (New England Biolabs, USA) or lambda phosphatase plus phosphatase 
inhibitors (already included in the lysis buffer), in 1x phosphatase buffer 
supplemented with 1 mM MnCl2 (New England Biolabs, USA). After treatment, whole 
cell extracts were prepared as described in the previous section.  
 
Recombinant PLK4 expression 
Recombinant pGEX-2RBS-GST-PLK4(WT), pGEX2RBS-GST-PLK4(WT) and 
pACYC-RIL λppase, and pGEX2-RBS-GST-PLK4(KD) were each transformed into 
Escherichia coli BL21 cells. PLK4 expression was induced with 1 mM IPTG for 6 hr 
at 25ºC. For detection of phosphorylated PLK4, the soluble fractions were prepared 
according to the procedures described above. 
 
In vitro auto-phosphorylation of PLK4 
Recombinant dephosphorylated His-MBP-PLK4(WT) was expressed and purified by 
the Protein Expression and Purification Core Facility, EMBL, Heidelberg, Germany. 
His-MBP-PLK4 was co-expressed with pACYC-RIL-λppase for dephosphorylation 
(Shrestha et al., 2012). For in vitro autophosphorylation assays, 50 to 800 M PLK4 
were incubated for 10 min at 18ºC in 50 mM Tris-HCl pH 7.5 buffer containing 1 mM 
ATP and 1 mM MgCl2.  
 
Immunoprecipitation  
Ten million cells were transiently transfected with pMT-GFP-PLK4(WT) or pMT-GFP-
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PLK4(SKL) and dsRNA against mCherry or SAS-6, and induced with 150 μM CuSO4 
for 15 hours. Cells were harvested and centrifuged at 1000 rpm for 5 min. The pellet 
was washed in PBS supplemented with protease inhibitors (Roche, USA) and snap 
frozen in liquid nitrogen. The pellet was then resuspended in 1 ml of lysis buffer and 
cell lysis was achieved with 4 consecutive freeze-thaw cycles (dry ice and 37ºC 
water bath). After centrifuging the lysates at 14,000 rpm for 30 min, 80 μl of GFP-
Trap beads (Chromotek, Germany) were added to each sample. Protein binding to 
the beads was performed on a rotating wheel at 4ºC for 3 hours followed by four 
washes in lysis buffer. PLK4 was retrieved from beads by adding 1x Laemmli buffer 
in lysis buffer and boiling the samples at 99ºC for 5 min.  
 
Western blotting  
Standard western blotting procedures involved blocking in TBS-T (0.1% Triton X-100 
in TBS) supplemented with 5% milk powder, and 1% milk powder in TBS-T for 
antibody incubations and washes. For detection with phospho-specific antibodies, 
blocking was performed in TBS supplemented with 5% BSA and phosphatase 
inhibitors (50 mM NaF, and 5 mM Na3VO4), primary antibody incubations were 
performed in TBS-T supplemented with 5% BSA and phosphatase inhibitors and 
secondary antibody incubations were performed in 5% BSA and phosphatase 
inhibitors supplemented with 0.01% SDS, while washes were performed in TBS-T.  
 
Immunostaining 
DMEL cells were plated onto glass coverslips, allowed to adhere for 1h and post-
fixed in 4% formaldehyde in PHEM buffer (60 mM PIPES pH 6.8, 25 mM HEPES pH 
7.0, 10 mM EGTA, 4 mM MgCl2). Cells were permeabilized and washed in PBSTB 
(PBS containing 0.1% Triton X-100 and 1% BSA). Immunostainings were performed 
as previously described (Rodrigues-Martins et al., 2007). Cells were mounted with a 
mounting medium containing DAPI to stain DNA (Vectashield, Vector Laboratories, 
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USA). Cell imaging and centriole scoring were performed on a Leica DMRA2 
microscope with a Cool SNAP HQ camera (Photometrics), or with a Nikon Eclipse Ti-
E (Nikon) microscope with a Evolve EMCCD camera (Photometrics) and controlled 
by MetaMorph 7.5 software (Molecular Devices). Images were acquired as a Z-series 
(0.3 μm z-interval) and are presented as maximal intensity projections. All images 
were prepared with Adobe Photoshop and Illustrator (Adobe Systems, USA) and 
ImageJ (NIH, USA). Super-Resolution structured illumination images were acquired 
using the Zeiss LSM780 ELYRA PS1 (SR-SIM) microscope. All data were captured 
using a 63x oil objective. ZEISS immersion oil 1.513 was applied. Images were 
collected and processed using Zeiss Zen software.  
 
Phospho-specific antibodies 
Rabbit p-PLK4 Thr172 polyclonal antibody was synthesized, purified and purchased 
from PhosphoSolutions (Colorado, USA). Short phospho-peptide spanning the 
Thr172 residue was used for the production of the antibody. Rabbit p-PLK4 Ser293 
has been described elsewhere (Cunha-Ferreira et al., 2013). Dot blots were 
performed against the two antibodies with S293A and T172A mutant phospho-
peptides validating these as phospho-antibodies (data not shown). For western blot 
of whole cell extracts, p-PLK4 Thr172 was used at 1:300 dilutions. To detect 
bacterially expressed PLK4, p-PLK4 Thr172 and p-PLK4 Ser293 antibodies was 
used at 1:10000 dilution. All antibodies were supplemented with the corresponding 
non-phosphorylated peptide at 1000 ng/ml in TBST supplemented with 5% BSA and 
phosphatase inhibitors for western blot as previously described.  
 
Antibodies  
The antibodies used for western blotting were the following: mouse GFP (1:100 
dilution, Roche, USA), mouse cMyc (1:500 dilution, clone 9E10, Santa Cruz 
Biotechnology, USA), mouse GST (1:10000, clone 26H1, Cell Signalling USA), 
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mouse Histidine (1:2500, Novagen, USA), rabbit actin (1:2000, Sigma, USA), rabbit 
PLK4 antibody (1:100 dilution (Cunha-Ferreira et al., 2009)), and rabbit Asterless 
(1:1000, was a kind gift from Dr. David Glover, University of Cambridge, UK). HRP 
secondary antibodies (Jackson Immunoresearch Laboratories, USA) and IRDye 
secondary antibodies (Odyssey, LI-COR Biosciences) were used at 1:10000 dilution. 
The primary antibodies used in immunostaining were the following: chicken anti-
Drosophila-PLP (1:1000 dilution (Rodrigues-Martins et al., 2007)), mouse cMyc 
(1:1500 dilution, clone 9E10, Santa Cruz Biotechnology, USA) and rabbit Asterless 
(1:1000). Secondary antibodies with minimal cross reactivity against other species 
were used as follows: Rhodamine Redex, FITC, and Cy5 were used at 1:100 
dilutions (Jackson Immunoresearch, USA), and Alexa 350 was used at 1:50 dilution 
(Molecular Probes, USA).  
 
Centrosome scoring 
Number codes were assigned to both control and sample slides in order to score 
centrioles as a blind assay. A total of 100 cells were scored per sample per slide. 
Cells were categorized according to the number of centrioles (0 to 1, 2 to 4 or more 
than 4). 
 
Fly stocks and husbandry 
Control (RFP::PACT/UASGFP::PLK4; +/+) and PLK4 overexpressing 
(RFP::PACT/UASGFP::PLK4; BamGal4/+) flies (Cunha-Ferreira et al., 2013) were 
grown in normal corn meal media at different temperature ranging from 16ºC to 25ºC. 
  
Testes sample preparation, imaging and analysis 
To measure the total amount of PLK4, intact testes from 0-1 day old adult males 
expressing GFP::PLK4 were dissected in testes buffer (183 mM KCl, 47 mM NaCl, 1 
mM EDTA and 10 mM Tris-HCl pH 6.8) and fixed in 4% formaldehyde for 20 min. 
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Intact testes were then washed and mounted using Vectashield (Vector Laboratories, 
USA) mounting media for imaging. Samples were imaged for GFP::PLK4 on a Leica 
SPX5 confocal microscope and total GFP fluorescence in the whole testes was 
measured using Imaris 7.7. To study the centriole amplification, testes from 0-1 day 
old adults were dissected in testes buffer, transferred to poly-L-lysine glass slides 
(Sigma, USA), squashed and frozen in liquid nitrogen as previously described (Cenci 
et al., 1994). Samples were fixed for 8 min in dry ice-cold methanol followed by 10 
min in acetone. DNA was stained with DAPI. Testes were mounted using Vectashield 
(Vector Laboratories, USA) mounting media for imaging. Samples were imaged as a 
Z-series (0.3 μm z-interval and 0.04 µm XY-pixel size) on a Leica SPX5 confocal 
microscope. Images are presented as 3D projections using Imaris 7.8. 
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Figure Legends 
Figure 1 Drosophila PLK4 Thr172 is a conserved phosphorylation site required 
for kinase activity. A) Schematic representation of Drosophila PLK4 showing the 
Kinase domain, the Cryptic Polo-Box (PB1 and PB2) and the Polo-Box 3 (PB3). The 
sequence alignment of part of human (Hs) and Drosophila (Dm) PLK1 and PLK4 
activation segment is also represented. The threonine residue within the T-loop 
whose phosphorylation leads to PLK1 activation (Thr210/Thr182 in human and 
Drosophila PLK1, respectively) is highly conserved in PLK4 (Thr170/Thr172 in 
human and Drosophila PLK4, respectively). These residues are highlighted in red. B) 
PLK4 T172A mutant has residual catalytic activity. Expression of pMT-GFP-
PLK4(WT) (wild-type), GFP-PLK4(T172A) (Thr172 mutated to alanine) and GFP-
PLK4(KD) (kinase dead) after depletion of endogenous PLK4 (ePLK4 RNAi) in 
DMEL cells. Cell extracts were prepared and analyzed by western blot with p-PLK4 
Ser293 and GFP antibodies. Note that PLK4(WT) was loaded in excess to have 
similar amounts of the different constructs and thus facilitate comparison of the 
proportion of p-PLK4 Ser293 (see also Figure S1B). Autophosphorylation at the 
Ser293 residue (p-PLK4 Ser293) is used as a read-out of PLK4 activity as shown 
previously (Cunha-Ferreira et al., 2013). Quantification of the ratio of PLK4 
phosphorylated at Ser293 to the total amount of PLK4 (GFP-PLK4) is shown. The 
ratios were normalized to the WT kinase. Data are the average of 3 experiments ± 
SEM (* p<0.05, ** p<0.01, t-test).  (See also Figure S1A.) C-D) PLK4 T172A mutant 
expression cannot rescue loss of PLK4. C) Representative images of 
immunostaining of DMEL cells expressing act5-Myc-PLK4(WT), Myc-PLK4(T172A) 
or Myc-PLK4(KD) (in green) after depletion of endogenous PLK4 (ePLK4 RNAi). D-
PLP (Drosophila Pericentrin-Like Protein, a centriole marker, in red) and DAPI (DNA, 
in blue). Individual cells are outlined by dashed lines that represent the cell outline as 
judged by the D-PLP background signal. Transfected cells are indicated with an 
arrow. Note that T172A forms some agglomerates in the cytoplasm, as described 
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previously for KD (Klebba et al., 2013). Scale bar, 5 μm. D) Quantification of centriole 
number per cell. Data are the average of 3 experiments ± SEM. PLK4(T172A) and 
PLK4(KD) phenotype of ‘0-1’ is statistically different from that of PLK4(WT) (*** 
p<0.0001, Pearson’s χ2 test). Note that while PLK4(WT) can rescue PLK4 depletion 
phenotype, PLK4(T172A) cannot. Similar results in centriole biogenesis were 
obtained using pMT-GFP-PLK4 constructs (WT, T172A and KD) (not shown). 
 
Figure 2 Drosophila PLK4 trans-autophosphorylates the T-loop residue Thr172. 
A) PLK4 autophosphorylates Thr172 directly in bacteria. Soluble fractions of GST-
PLK4(WT), co-expressed or not with λppase, and GST-PLK4(KD) were probed by 
western blot with p-PLK4 Thr172 and GST antibodies. Phosphorylation of Thr172 
was detected in PLK4(WT), whereas there is no detectable phosphorylation in 
PLK4(WT) when co-expressed with λppase, or in PLK4(KD). Note that PLK4(WT) is 
hyperphosphorylated as there are no phosphatases in bacteria. B) PLK4 catalytic 
activity is needed for Thr172 phosphorylation in cells. Expression of pMT-GFP-
PLK4(WT), GFP-PLK4(T172A), GFP-PLK4(KD), GFP-PLK4(ND) (non-degradable) 
and GFP-PLK(KDND) after depletion of endogenous PLK4 (ePLK4 RNAi) in DMEL 
cells. Cell extracts were prepared and analyzed by western blot with p-PLK4 Thr172 
and GFP antibodies. PLK4(WT) was loaded in excess to have similar amounts of the 
different constructs and thus facilitating comparison of the proportion of p-PLK4 
Thr172 (see also Figure S1B). Note that only PLK4(WT) and PLK4(ND) are 
phosphorylated at Thr172. Quantification of the ratio of PLK4 phosphorylated at 
Thr172 to the total amount of PLK4 (GFP-PLK4) is shown. The ratios were 
normalized to the WT kinase. Data are the average of 3 experiments ± SEM (n.s. not 
significant, * p<0.05, ** p<0.01, t-test).  Note that the T172A lane does not show 
pThr172 signal, attesting to the specificity of the antibody (see also Figure S2A 
regarding the specificity of the antibody).  C) PLK4 trans-autophosphorylates the 
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Thr172 residue in vitro. Autophosphorylation of increasing concentrations of purified 
dephosphorylated His-MBP-PLK4 (50 to 800 M) 10 minutes after addition of ATP. 
Samples were probed by western blot with antibodies against p-PLK4 Thr172 and 
His (for total PLK4). Quantifications of the intensity of His-PLK4 phosphorylated at 
Thr172 and of the intensity of total His-PLK4 are shown. The values were normalized 
to the highest concentration analysed. Note that PLK4 autophosphorylation (p-PLK4 
Thr172) shows a trans, non-linear like behavior, different from the PLK4 total levels 
curve. (See also Figure S2B-C.) D-E) PLK4 trans-phosphorylates at Thr172 in cells. 
D) Schematic representation of PLK4 trans-phosphorylation experiment. E) 
Combinations (as indicated) of pMT-GFP-PLK4(WT), act5-Myc-PLK4(KD), pMT-
GFP(empty) and act5-Myc(empty) constructs were expressed in DMEL cells after 
depletion of endogenous PLK4. Cell extracts were prepared and analyzed by 
western blot with antibodies against GFP to detect GFP-PLK4(WT) and Myc to 
detect Myc-PLK4(KD). Note that in the presence of PLK4(WT), PLK4(KD) becomes 
phosphorylated (lower mobility bands) as detected by the use of p-PLK4 Thr172 
antibody (lower panel). 
 
Figure 3 Modelling of PLK4 autophosphorylation and the effect of centrosome-
dependent concentration of PLK4 on its activation. A) Reaction diagrams 
representing the cis- and trans-autophosphorylation of PLK4 (left and right panels, 
respectively) from a non-Thr172 phosphorylated ‘basal form’ with residual catalytic 
activity (B, in grey) to an activated form phosphorylated in the T-loop residue Thr172 
(A*, in green), and to doubly phosphorylated form targeted for degradation (A**, in 
green). The dark arrows indicate the critical flux regulated by either cis- or trans-
phosphorylation. The dashed arrows indicate the kinases catalyzing the 
phosphorylation steps. When the catalyst and the substrate are the same, the 
phosphorylation is in cis and described as a first order, linear kinetic. When the 
catalyst and substrate differ the kinetics is non linear. The top arrow describes the 
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translated PLK4 that enters the system. Lateral, outgoing arrows describe 
constitutive (thinner) and both constitutive and degron-induced (thicker) elimination of 
PLK4. B) Stable steady state concentrations of the activated and degradation-
targeted PLK4 (measured as A=A*+A**) as a function of the rate of PLK4 expression 
(parameter s) in a cis-autophosphorylation (continuous red line) and in a trans-
autophosphorylation mode (continuous green line). C) Reaction diagram 
representing the trans-autophosphorylation of PLK4 in a two-compartment model 
describing the conversion between the three PLK4 forms and their partitioning 
between the cytoplasm and the centrosome. D) The pie charts represent the 
proportion of basal (in grey) and activated (in green) forms both in the cytoplasm and 
centrosome, in the presence (‘+ Centrosome’, left) and in the absence of centrosome 
(‘- Centrosome‘, right). Three scenarios are illustrated: normal PLK4 production rate 
in the wild type (s = 0.1, top panel, -), moderate over expression (s = 1, middle panel, 
+) and strong overexpression (s = 10, bottom panel, ++). Note that: i) the proportion 
of activated PLK4 is always higher at the centrosome than cytoplasm; ii) within the 
same levels of overexpressed PLK4 (+ or ++), removal of the centrosome leads to an 
increase in the proportion of activated PLK4 in the cytoplasm; iii) only high 
overexpression of PLK4 (++) leads to a high proportion of activated species in the 
cytoplasm in the presence of a centrosome; iv) if PLK4 is not overexpressed (-) the 
proportion of activated species in the cytoplasm is not increased upon centrosome 
removal. The remaining parameters values were:  a = 40, b = 2, α = 40, c = 5, p = 10, 
d = 1, dc = 40, ρ = 2000, r1 = 5 parameters r2 = 1. For detailed description of the 
models see supplementary information. 
 
Figure 4 Localization of PLK4 to the centriole is important for its activation. A) 
PLK4(T172A) can localize to the centrosome. Structured illumination images of 
DMEL cells expressing pMT-PLK4(WT)-GFP and GFP-PLK4(T172A) after depletion 
of endogenous PLK4 (ePLK4 RNAi). Cells were immunostained with antibodies 
 35 
against Asterless (Asl, in red) and D-PLP (in blue). Note that both PLK4(WT) and 
PLK4(T172A) localize to the centrioles. Individual cells are outlined by dashed lines 
that represent the cell outline as judged by the D-PLP background signal. 
Enlargements of the centrosomes indicated by the arrowheads are shown. Scale bar, 
5 μm. B-E) Delocalization of PLK4 from the centrosome, through Asl depletion, leads 
to its reduced activation. DMEL cells were depleted of Asl (Asl RNAi) (mCherry RNAi 
was used as a negative control) for 4 days, after depletion of endogenous PLK4 
(ePLK4 RNAi), and followed by transient transfection with pMT-PLK4(WT)-GFP. B) 
Representative structured illumination images. Asl in red, D-PLP in blue. Insets show 
magnification of centriole. Individual cells are outlined by dashed lines that represent 
the cell outline as judged by the D-PLP background signal. Enlargements of the 
centrosomes indicated by the arrowheads are shown. Scale bar, 5 μm. C) Cell 
extracts were prepared and analyzed by western blot. Depletion of Asl was 
confirmed using actin as a loading control. D) Quantification of centriole number per 
cell. Data are the average of 3 experiments ± SEM. Note that ‘0-1’ phenotype in Asl 
depletion is statistically different from that of the control (mCherry RNAi) (*** 
p<0.0001, Pearson’s χ2 test). E) Cell extracts were prepared and analysed by 
western blot. Activity of PLK4 at Thr172 was assessed using antibodies against p-
PLK4 Thr172 and GFP. mCherry control sample was loaded in excess to facilitate 
the comparison of the proportion of p-PLK4 Thr172. Quantification of the ratio of 
PLK4 phosphorylated at Thr172 to the total amount of PLK4 (PLK4-GFP) is shown. 
The ratios were normalized to the control. Data are the average of 3 experiments ± 
SEM (* p<0.05, t-test).   
 
Figure 5 Concentrating PLK4 is sufficient for its activation. A) Construction of 
Drosophila PLK4 with tripeptide targeting it to the peroxisome (SKL). B) PLK4(SKL) 
is targeted to the peroxisome. Immunostaining of DMEL cells expressing pMT-GFP-
PLK4(WT) or GFP-PLK4(SKL) and act5-mCherry-SKL (peroxisomal marker, in red) 
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with D-PLP (in blue). Percentage of cells with PLK4(SKL) localising to the 
peroxisome (P), centrosome (C) and both peroxisome and centrosome (P+C) is 
indicated in each merged image. Individual cells are outlined by dashed lines that 
represent the cell outline as judged by the D-PLP background signal. Enlargements 
of the indicated areas (squares) are shown. Scale bar, 10 μm. C-D) PLK4 is 
activated at the peroxisome and on beads. Expression of pMT-GFP-PLK4(WT) or 
GFP-PLK4(SKL) (peroxisome-targeted PLK4) after depletion of SAS-6 (SAS-6 RNAi) 
(mCherry RNAi used as a negative control) in DMEL cells for 12 days. C) 
Quantification of centriole number per cell. Note that ‘0-1’ phenotype in SAS-6 
depletion is statistically different from that of the control (mCherry RNAi) (*** 
p<0.0001, Pearson’s χ2 test). D) Cell extracts were prepared and analyzed by 
western blot with p-PLK4 Thr172 and PLK4 antibodies. mCherry control samples 
were loaded in excess to have similar amount of PLK4 and thus facilitating 
comparison of the proportion of p-PLK4 Thr172 (see also Figure S3). GFP-
PLK4(WT) was immunoprecipitated and sequentially detected on western blot with p-
PLK4 Thr172 and PLK4 antibodies. Quantification of the ratio of PLK4 
phosphorylated at Thr172 to the total amount of PLK4 is shown. The ratios were 
normalized to mCherry GFP-PLK4(WT) control. E) PLK4 Thr172 phosphorylation is 
proportional to PLK4 concentration. Peroxisome-targeted PLK4 is more 
phosphorylated in Thr172. Increased levels of expression of pMT-GFP-PLK4(SKL) in 
DMEL cells shows that PLK4(SKL) has increased kinase activity as measured by 
western blot with the p-PLK4-Thr172 antibody. PLK4 antibody was used for total 
PLK4 detection. The ratios of p-PLK4-Thr172 to the total amount of PLK4 loaded are 
shown. The ratios were normalized to the 150 M CuSO4-induced GFP-PLK4(WT) 
control. We used all PLK4 bands detected, including all the reduced gel mobility 
bands, for quantification in D and E.  
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Figure 6 High levels of PLK4 can overcome the inhibition of de novo 
biogenesis. A) Schematic representation of early stages of Drosophila 
spermatogenesis. The division of a stem cell originates a gonial cell that undergoes 
four rounds of incomplete mitotic divisions to produce a cyst of 16 primary 
spermatocytes. Primary spermatocytes undergo a long G2 phase, during which two 
pairs of centrioles elongate to form very long centrioles (~1.25 µm). B) PLK4 
overexpression levels can be controlled in vivo. Quantification of total overexpressed 
GFP-PLK4 levels in whole mounted testes of flies grown at different temperatures 
ranging from 16ºC to 25ºC. a.u., arbitrary units. C-F) Varying levels of PLK4 
overexpression lead to different pathways of centriole assembly in vivo. C) 
Representative images of primary spermatocytes overexpressing different levels of 
GFP-PLK4. A representative image of a control spermatocyte grown at 25⁰C is 
shown. Control flies always displayed these features at all temperatures (data not 
shown). Centrioles and DNA are marked using RFP-PACT (PACT is the centriole-
targeting domain of Drosophila pericentrin, red) and DAPI (blue), respectively. Insets 
show enlargements of the centrosomes indicated by the arrowheads. Scale bar, 5 
μm. D) Quantification of the total number of centrioles per spermatocyte from the flies 
grown at different temperatures ranging from 16ºC to 25ºC. E) The histogram shows 
the percentage distribution of all different cell types observed, classified according to 
their number of centrosomes and centrioles. All spermatocytes were classified into 
four categories: 1) Type I: spermatocytes containing only two centrosomes, each 
consisting of two centrioles. Note that this category was only observed in control 
cells. 2) Type II: spermatocytes having more than two centrosomes: two with WT-like 
configuration (containing two centrioles), others containing only single centrioles. 
Note that we never observed this type of cells. 3) Type III: spermatocytes showing 
only two centrosomes, each containing supernumerary centrioles, i.e, 3 to 7 
centrioles in a rosette-like configuration. 4) Type IV: spermatocytes containing at 
least 3 centrosomes: two in a rosette-like configuration and the remaining 
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centrosome containing 1 to 7 centrioles. While it is formally possible that some 
centrioles could break from a rosette and reduplicate further, we saw supernumerary 
centrosomes early in the 16 cells stage supporting the conclusion that most clusters 
are formed de novo. Presently, it is also difficult to assert whether the de novo 
formed centrioles within a centrosome form all at the same time or whether some 
centriole(s) form de novo and others subsequently amplify canonically within a 
centrosome. F) Quantification of the total number of supernumerary centrosomes 
(i.e. additional to the 2 centrosomes observed in WT cells) observed per 
spermatocyte at different PLK4 levels. The centriole numbers in these centrosomes 
vary from 1 to 7. Error bars represent ± SD in all graphs. 
 
Figure 7 Distribution of active PLK4 controls different pathways of centriole 
assembly in the cell. Schematic representation of the different pathways of centriole 
formation in cells with (A) and without (B) pre-existing centrioles, according to 
varying levels of PLK4. A) In a cell with a pre-existing centriole, we described three 
possibilities of centriole formation in this manuscript: i) in wild type cells, 
endogenously expressed PLK4 is concentrated and thus activated at the existing 
centriole, leading to canonical centriole biogenesis; ii) at low levels of PLK4 
overexpression (OE), higher amounts of PLK4 concentrate and activate at the 
existing centriole, therefore promoting canonical centriole amplification (rosette-like), 
iii) at higher levels of PLK4 overexpression, PLK4’s concentration is sufficient to 
promote its activation at the centrosome as well as in the cytoplasm, leading to both 
canonical and de novo amplification. B) In a cell naturally without centrioles, such as 
the wild type unfertilized Drosophila egg, PLK4 is expressed at endogenous levels 
and no centrioles are formed de novo (Rodrigues-Martins et al., 2007); upon PLK4 
overexpression, de novo amplification occurs (Rodrigues-Martins et al., 2007), 
presumably because PLK4 levels in the cytoplasm are sufficiently high to activate 
itself. Note that in human cultured cells de novo centrioles biogenesis can occur after 
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laser ablation of pre-existing centrioles without overexpression of PLK4 (LaTerra et 
al., 2005). The mechanism underlying this phenomenon is still unknown; perhaps 
these cells have intrinsically higher endogenous PLK4 levels, or centrosome removal 
could lead to up-regulation of PLK4.  
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Supplementary information 
Mathematical models of Polo-like-kinase 4 activity 
We first considered a simple model of PLK4 activation in cis and in trans ignoring its 
localization in either the cytoplasm or the centrosome. The model features three 
forms of PLK4: a non-phosphorylated form, the active form phosphorylated in the T-
loop, and the active form phosphorylated in both T-loop and degron. The dynamics of 
the concentrations of these forms, denoted respectively B, A* and A**, are described 
by the following differential equations: 
 
where the A = A* + A** measures the sum of the two forms of active PLK4 kinases. 
The parameter s is the rate of synthesis of PLK4 (produced in the non-
phosphorylated form); the right-hand side terms dB and dA* represent the first order 
degron-independent degradation of non-phosphorylated and T-loop phosphorylated 
forms, respectively; dcA** represents the first-order degron-dependent degradation of 
the double phosphorylated form; and the term cAA* measures the trans-
autophosphorylation of the active form in the degron. Finally, the terms aBA and bB2 
represent the phosphorylation of the non-phosphorylated PLK4 mediated by itself in 
trans and by the active form, respectively, while αB represents the cis-
phosphorylation of the non-phosphorylated PLK4 form. This general formulation is 
convenient because by setting a to a positive value and  to zero, we define the 
scenario were activation acts only in trans-autophosphorylation, while by setting a to 
zero and  to a positive value defines the scenario of PLK4 cis-phosphorylation or 
PLK4 phosphorylation by another unspecified kinase, assumed to be at constant 
concentration. 
Supplemental Text
 2 
 We then extended the simple model formulated above to describe the 
exchange of the three forms of PLK4 and their partition between two compartments, 
the cytoplasm and the centrosome. The concentrations of each PLK4 form in either 
cytoplasm and centrosome is specific by the subindexes 1 or 2, respectively. The 
two-compartment model is described by the following 6 differential equations: 
 
where Ai = A*i + A*i* denote the total concentration of the two active (T-loop 
phosphorylated) PLK4 forms in the compartment indexed i. r1  and r2 are the rate 
constants of the fluxes from the cytoplasm to the centrosome and vice-versa, 
respectively.  denotes the volume ratio between cytoplasm and centrosome. The 
remaining parameters are defined as above. It is assumed that PLK4 is produce in 
non-phosphorylated form into the cytoplasm. The single and the two compartment 
model were analyzed by deriving the equilibrium solutions obtained when the left-
hand side is set to zero and the system of equations solved in order of the 3 or 6 
variables. Analytical and numeric equilibrium solutions were obtained using the 
software Mathematica 4.2 (Wolfram). The absolute quantity of the basal and active 
PLK4 forms in the two-compartment model were calculated as B1 +B2 and A1 +A2, 
respectively. Unless when otherwise indicated, the following set of reference 
parameters were used in all the figures of this article: s = 0.1, a = 40, b = 2,  = 40, c 
= 5, p = 10, d = 1, dc  = 40,  = 2000, r1 = 5 and r2 = 1. 
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Supplementary Experimental Procedures 
In vitro kinase assay 
In vitro kinase assay was performed using similar amounts of immunoprecipitated 
GFP-PLK4(WT), GFP-PLK4(T172A) and GFP-PLK4(KD) that were transiently 
expressed individually in DMEL cells previously treated with dsRNA for endogenous 
PLK4 (ePLK4 RNAi). 50 µl of Dynabeads coupled to GFP antibody were used to 
immunoprecipitate each construct. The beads were divided in two: half was used for 
the radioactive kinase assay and the other half to probe the total level of 
immunoprecipitated kinase by western blot. The radioactive in vitro kinase assay was 
performed with different GFP-PLK4 constructs in presence of 2 µg of MBP (Myelin 
Basic Protein, Santa Cruz) and 1 μCi of ATPγP32. The mixtures were incubated 30 
min at 18°C in the phosphorylation buffer (25 mM Tris pH7.5, 10 mM MgCl2, 1 mM 
DTT). Kinase reactions were stopped and analyzed by SDS-PAGE. 
 
Non-radioactive in vitro kinase assays 
For non-radioactive kinase assays, 500 ng of recombinant His-MBP (Maltose Binding 
Protein)-PLK4 (pre-activated or not with regular ATP 1mM for 20 min) were diluted in 
the phosphorylation buffer in presence of 2 mM ATPS (Abcam) and 5 µg MBP 
(Myelin Basic Protein) for 1 min at 18°C. The reactions were stopped with 80 mM 
EDTA and incubated for 2 hours with 1 mM 4-Nitrobenzyl mesylate (PNBM, Abcam) 
at RT to alkylate the thiophosphorylation site on the substrate. The kinase reaction 
was stopped and analysed by immunoblot using anti thiophosphate-ester (clone 51-
8, Abcam) that recognises the phosphorylated MBP (Myelin Basic Protein).  
 
In vitro auto-phosphorylation of PLK4 
For in vitro autophosphorylation assays, His-MBP (Maltose Binding Protein)-
PLK4(WT) was incubated for 10 min at 18ºC in 50 mM Tris-HCl pH 7.5 buffer 
 4 
containing 1 mM ATP and 1 mM MgCl2. Time points were taken every 2.5 min for 
testing autophosphorylation over the course of the experiment. 
 
Supplementary Figure Legends 
Figure S1 (related to Figure1) A) PLK4 Thr172 is required for PLK4 kinase 
activity. Following expression in DMEL cells depleted of endogenous PLK4 (ePLK4 
RNAi), pMT-GFP-PLK4(WT), GFP-PLK4(T172A) and GFP-PLK4(KD) were 
immunoprecipitated with antibodies against GFP and used for kinase assays with 
MBP (Myelin Basic Protein) as a substrate. Autoradiograph (P32) for the MBP is 
shown. The amount of immunoprecipitated kinase was analyzed by western blot with 
antibodies against GFP. Coomassie stained gel shows the total MBP present as a 
substrate. Quantification of levels of MBP phosphorylation is shown. The values were 
normalized to the WT kinase. Data are the average of 3 experiments ± SEM (** 
p<0.01, *** p<0.0001 t-test). B) T172A mutant is more stable than WT PLK4. 
Expression of pMT-GFP-PLK4(WT), GFP-PLK4(T172A) and GFP-PLK4(KD) after 
depletion of endogenous PLK4 (ePLK4 RNAi) in DMEL cells. Cell extracts were 
prepared and analyzed by western blot with antibodies against GFP and actin. Equal 
amounts of each extract were loaded. Actin was used as a loading control. Similar 
results were observed using the constructs from Figure 1C-D (i.e. Myc tagging) (not 
shown). 
 
Figure S2 (related to Figure 2) A) p-PLK4 Thr172 is a phospho-specifc antibody 
raised against PLK4 Thr172 residue. DMEL cells expressing pMT-GFP-PLK4 were 
lysed and treated with lambda phosphatase (λ-ppase), λppase plus phosphatase 
inhibitors (PI) or PI alone. Upon PI treatment, the p-PLK4 Thr172 antibody 
recognizes a single western blot band corresponding to GFP-PLK4 phosphorylated 
at the Thr172. Note that this band is absent from the λ-ppase treated sample. B) 
PLK4 autophosphorylates the Thr172 residue in vitro. Autophosphorylation of 
 5 
purified dephosphorylated His-MBP (Maltose Binding Protein)-PLK4(WT) followed for 
10 minutes (min) after addition of ATP. Samples were taken at the indicated time 
points and probed by western blot with p-PLK4 Thr172 and His antibodies. Note that 
a very faint signal can be seen as soon as ATP is added (0 min). Quantification of 
the ratio of His-MBP-PLK4 phosphorylated at Thr172 to the total amount of PLK4 
(His) is shown. The values were normalized to time point 10 min. Data are the 
average of 3 experiments ± SEM. Note that phosphorylation at Thr172 occurred very 
early and appears to increase non-linearly with time. C) Pre-autophosphorylation 
of PLK4 activates this kinase. Step 1: “Activation” – Dephosphorylated His-MBP 
(Maltose Binding Protein)-PLK4(WT) was either incubated with regular ATP (+) or not 
(-). Step 2: “Kinase assay” – PLK4 from Step 1 was used for kinase assays using 
MBP (Myelin Basic Protein) as a substrate in the presence of ATPS. Samples were 
probed by western blot with antibodies against p-PLK4 Thr172 and His to detect 
phosphorylation on Thr172 and total levels of PLK4, respectively (after Step 1). MBP 
(Myelin Basic Protein) was equally loaded across lanes and its phosphorylation was 
analyzed by SDS-PAGE. Quantification of the ratio of MBP phosphorylation to the 
total amount of PLK4 (His) is shown. The ratios were normalized to the “non-active” 
kinase. A representative experiment is shown (out of 2). Note that because PLK4 
activates itself extremely fast, PLK4 is also autoactivating in the presence of ATPS 
in Step 2, thus becoming partly active during the kinase assay. Therefore, even this 
“non-activated” kinase shows some ability to phosphorylate the substrate. 
Nevertheless, we can observe a difference in catalytic activity when comparing: with 
and without “pre-activation”.  
 
Figure S3 (related to Figure 5) A) PLK4 is more stable in the absence of 
centrosomes. Expression of pMT-GFP-PLK4(WT) and pMT-GFP-PLK4 (ND) 
(cannot be targeted for degradation, see Figure 2B) in DMEL cells after depletion of 
 6 
SAS-6 (SAS-6 RNAi) for 12 days to remove centrosomes (mCherry RNAi used as a 
negative control) and depletion of endogenous PLK4 (ePLK4 RNAi). Cell extracts 
were prepared and analyzed by western blot with antibodies against GFP and actin. 
Equal amounts of each extract were loaded. Actin was used as a loading control. A 
representative experiment is shown (out of 3). Note that PLK4(WT) is significantly 
stabilized in the absence of centrosomes. This large difference is likely to result from 
degradation since it was not observed with a non-degradable (ND) construct. Similar 
results were observed in the absence of Asl (not shown). B) PLK4(SKL) does not 
co-localize with Ana2 outside the centrosome. Representative images of 
immunostaining of DMEL cells expressing GFP-PLK4(SKL) after depletion of SAS-6 
(SAS-6 RNAi) (mCherry RNAi used as a negative control) for 12 days. D-PLP (in 
blue) and Ana2 (in red (Antibody from Dzhindzev et al, 2014)). Individual cells are 
outlined by dashed lines that represent the cell outline as judged by the D-PLP 
background signal. Scale bar, 10 μm. Enlargements of the indicated areas 
(squares) are shown. Arrows in enlargements (top panel) indicate GFP-PLK4(SKL) 
co-localizing with Ana2 at the centrosome (D-PLP). Note that GFP-PLK4(SKL), 
which we have shown to localize to the peroxisome and centrosome (Figure 5 in the 
main manuscript) only co-localizes with Ana2 at the centrosome, and not at the 
peroxisome. This suggests that in the absence of centrosomes, overexpressed PLK4 
can autoactivate at the lumen of the peroxisome, where no Ana2/STIL is detected. 
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